Top

Published in:

Open Access 01-03-2020 | Bladder Carcinoma | Original Article

Microlocalization and clinical significance of stabilin-1⁺ macrophages in treatment-naïve patients with urothelial carcinoma of the bladder

Authors: Bo Wang, Hao Huang, Meihua Yang, Wenjuan Yang, Zhuowei Liu, Weibin Hou, Hong Zeng, Zhihua He, Tianxin Lin, Jian Huang

Published in: World Journal of Urology | Issue 3/2020

Abstract

Purpose

Emerging evidence has shown that macrophages (Mφs) at different tumor sites have diverse clinical attributes. Stabilin-1 is a multi-functional scavenger marker for specialized tumor-associated Mφs. This study investigates the relationship between the density and microlocalization of stabilin-1⁺ Mφs within tumors and the clinical outcomes of patients with urothelial carcinoma of the bladder (UCB).

Methods

In this retrospective study, 283 UCB patients who received radical cystectomy or transurethral resection were examined. Immunohistochemistry and immunofluorescence analyses were used to colocalize the expression of stabilin-1 with other markers for Mφs (CD14, CD68, CD163, and CD206). Kaplan–Meier analysis and Cox proportional hazards regression models were applied to estimate overall survival (OS) and recurrence-free survival (RFS).

Results

In UCB tissues, stabilin-1 was primarily expressed on Mφs, as evident from triple immunofluorescence staining for stabilin-1 and Mφ markers. Stabilin-1⁺ Mφs were often more prominent in stromal regions rather than intratumoral regions in UCB tissues (P < 0.0001). After dichotomization at the median cell density for stabilin-1⁺ Mφs, only intratumoral stabilin-1⁺ Mφ density was a predictor of poor OS (P < 0.001) and RFS (P = 0.026). Moreover, intratumoral stabilin-1⁺ Mφ density was positively associated with tumor stage (P < 0.01) and histological grade (P < 0.01), and emerged as an independent prognostic factor for OS (HR 2.371; P < 0.0001), but not for RFS (HR 1.491; P = 0.061).

Conclusions

Our findings indicate that intratumoral stabilin-1⁺ Mφs could potentially be used as a pro-tumoral prognostic marker for UCB patients.

Available only for authorised users

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J (2016) Cancer statistics in China. CA Cancer J Clin 66(2):115–132. https://doi.org/10.3322/caac.21338 CrossRefPubMed

Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat EM, Hernandez V, Kaasinen E, Palou J, Roupret M, van Rhijn BW, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71(3):447–461. https://doi.org/10.1016/j.eururo.2016.05.041 CrossRefPubMed

Huang J, Lin T, Liu H, Xu K, Zhang C, Jiang C, Huang H, Yao Y, Guo Z, Xie W (2010) Laparoscopic radical cystectomy with orthotopic ileal neobladder for bladder cancer: oncologic results of 171 cases with a median 3-year follow-up. Eur Urol 58(3):442–449. https://doi.org/10.1016/j.eururo.2010.05.046 CrossRefPubMed

Alfred Witjes J, Lebret T, Comperat EM, Cowan NC, De Santis M, Bruins HM, Hernandez V, Espinos EL, Dunn J, Rouanne M, Neuzillet Y, Veskimae E, van der Heijden AG, Gakis G, Ribal MJ (2017) Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 71(3):462–475. https://doi.org/10.1016/j.eururo.2016.06.020 CrossRefPubMed

Ku JH, Kang M, Kim HS, Jeong CW, Kwak C, Kim HH (2015) Lymph node density as a prognostic variable in node-positive bladder cancer: a meta-analysis. BMC Cancer 15:447. https://doi.org/10.1186/s12885-015-1448-x CrossRefPubMedPubMedCentral

Horn T, Laus J, Seitz AK, Maurer T, Schmid SC, Wolf P, Haller B, Winkler M, Retz M, Nawroth R, Gschwend JE, Kubler HR, Slotta-Huspenina J (2016) The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer. World J Urol 34(2):181–187. https://doi.org/10.1007/s00345-015-1615-3 CrossRefPubMed

Taniguchi K, Karin M (2018) NF-kappaB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol 18(5):309–324. https://doi.org/10.1038/nri.2017.142 CrossRefPubMed

Chaffer CL, Weinberg RA (2011) A perspective on cancer cell metastasis. Science 331(6024):1559–1564. https://doi.org/10.1126/science.1203543 CrossRefPubMed

Okabe Y, Medzhitov R (2016) Tissue biology perspective on macrophages. Nat Immunol 17(1):9–17. https://doi.org/10.1038/ni.3320 CrossRefPubMed

10.

Epelman S, Lavine KJ, Randolph GJ (2014) Origin and functions of tissue macrophages. Immunity 41(1):21–35. https://doi.org/10.1016/j.immuni.2014.06.013 CrossRefPubMedPubMedCentral

11.

Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P (2017) Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 14(7):399–416. https://doi.org/10.1038/nrclinonc.2016.217 CrossRefPubMedPubMedCentral

12.

Qian BZ, Pollard JW (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141(1):39–51. https://doi.org/10.1016/j.cell.2010.03.014 CrossRefPubMedPubMedCentral

13.

Guerriero JL (2018) Macrophages: the road less traveled, changing anticancer therapy. Trends Mol Med 24(5):472–489. https://doi.org/10.1016/j.molmed.2018.03.006 CrossRefPubMedPubMedCentral

14.

Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4(1):71–78. https://doi.org/10.1038/nrc1256 CrossRefPubMed

15.

Chevrier S, Levine JH, Zanotelli VRT, Silina K, Schulz D, Bacac M, Ries CH, Ailles L, Jewett MAS, Moch H, van den Broek M, Beisel C, Stadler MB, Gedye C, Reis B, Pe’er D, Bodenmiller B (2017) An immune atlas of clear cell renal cell carcinoma. Cell 169(4):736–749 e718. https://doi.org/10.1016/j.cell.2017.04.016 CrossRefPubMedPubMedCentral

16.

Kzhyshkowska J, Mamidi S, Gratchev A, Kremmer E, Schmuttermaier C, Krusell L, Haus G, Utikal J, Schledzewski K, Scholtze J, Goerdt S (2006) Novel stabilin-1 interacting chitinase-like protein (SI-CLP) is up-regulated in alternatively activated macrophages and secreted via lysosomal pathway. Blood 107(8):3221–3228. https://doi.org/10.1182/blood-2005-07-2843 CrossRefPubMed

17.

David C, Nance JP, Hubbard J, Hsu M, Binder D, Wilson EH (2012) Stabilin-1 expression in tumor associated macrophages. Brain Res 1481:71–78. https://doi.org/10.1016/j.brainres.2012.08.048 CrossRefPubMed

18.

Riabov V, Yin S, Song B, Avdic A, Schledzewski K, Ovsiy I, Gratchev A, Llopis Verdiell M, Sticht C, Schmuttermaier C, Schonhaber H, Weiss C, Fields AP, Simon-Keller K, Pfister F, Berlit S, Marx A, Arnold B, Goerdt S, Kzhyshkowska J (2016) Stabilin-1 is expressed in human breast cancer and supports tumor growth in mammary adenocarcinoma mouse model. Oncotarget 7(21):31097–31110. https://doi.org/10.18632/oncotarget.8857 CrossRefPubMedPubMedCentral

19.

Karikoski M, Marttila-Ichihara F, Elima K, Rantakari P, Hollmen M, Kelkka T, Gerke H, Huovinen V, Irjala H, Holmdahl R, Salmi M, Jalkanen S (2014) Clever-1/stabilin-1 controls cancer growth and metastasis. Clin Cancer Res 20(24):6452–6464. https://doi.org/10.1158/1078-0432.CCR-14-1236 CrossRefPubMed

20.

Palani S, Maksimow M, Miiluniemi M, Auvinen K, Jalkanen S, Salmi M (2011) Stabilin-1/CLEVER-1, a type 2 macrophage marker, is an adhesion and scavenging molecule on human placental macrophages. Eur J Immunol 41(7):2052–2063. https://doi.org/10.1002/eji.201041376 CrossRefPubMed

21.

Buldakov M, Zavyalova M, Krakhmal N, Telegina N, Vtorushin S, Mitrofanova I, Riabov V, Yin S, Song B, Cherdyntseva N, Kzhyshkowska J (2017) CD68⁺, but not stabilin-1⁺ tumor associated macrophages in gaps of ductal tumor structures negatively correlate with the lymphatic metastasis in human breast cancer. Immunobiology 222(1):31–38. https://doi.org/10.1016/j.imbio.2015.09.011 CrossRefPubMed

22.

Wang B, Wu S, Zeng H, Liu Z, Dong W, He W, Chen X, Dong X, Zheng L, Lin T, Huang J (2015) CD103⁺ tumor infiltrating lymphocytes predict a favorable prognosis in urothelial cell carcinoma of the bladder. J Urol 194(2):556–562. https://doi.org/10.1016/j.juro.2015.02.2941 CrossRefPubMed

23.

Wang B, Liu H, Dong X, Wu S, Zeng H, Liu Z, Wan D, Dong W, He W, Chen X, Zheng L, Huang J, Lin T (2015) High CD204⁺ tumor-infiltrating macrophage density predicts a poor prognosis in patients with urothelial cell carcinoma of the bladder. Oncotarget 6(24):20204–20214. https://doi.org/10.18632/oncotarget.3887 CrossRefPubMedPubMedCentral

24.

Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence T, Locati M, Mantovani A, Martinez FO, Mege JL, Mosser DM, Natoli G, Saeij JP, Schultze JL, Shirey KA, Sica A, Suttles J, Udalova I, van Ginderachter JA, Vogel SN, Wynn TA (2014) Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41(1):14–20. https://doi.org/10.1016/j.immuni.2014.06.008 CrossRefPubMedPubMedCentral

25.

Wu Y, Zheng L (2012) Dynamic education of macrophages in different areas of human tumors. Cancer Microenviron 5(3):195–201. https://doi.org/10.1007/s12307-012-0113-z CrossRefPubMedPubMedCentral

26.

Fridman WH, Pages F, Sautes-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12(4):298–306. https://doi.org/10.1038/nrc3245 CrossRefPubMed

27.

Ruffell B, Affara NI, Coussens LM (2012) Differential macrophage programming in the tumor microenvironment. Trends Immunol 33(3):119–126. https://doi.org/10.1016/j.it.2011.12.001 CrossRefPubMedPubMedCentral

28.

Algars A, Irjala H, Vaittinen S, Huhtinen H, Sundstrom J, Salmi M, Ristamaki R, Jalkanen S (2012) Type and location of tumor-infiltrating macrophages and lymphatic vessels predict survival of colorectal cancer patients. Int J Cancer 131(4):864–873. https://doi.org/10.1002/ijc.26457 CrossRefPubMed

29.

Bostrom MM, Irjala H, Mirtti T, Taimen P, Kauko T, Algars A, Jalkanen S, Bostrom PJ (2015) Tumor-associated macrophages provide significant prognostic information in urothelial bladder cancer. PLoS One 10(7):e0133552. https://doi.org/10.1371/journal.pone.0133552 CrossRefPubMedPubMedCentral

30.

Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, Sun J, Wargo J, Blando J, Sharma P (2017) VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med 23(5):551–555. https://doi.org/10.1038/nm.4308 CrossRefPubMedPubMedCentral

31.

Rantakari P, Patten DA, Valtonen J, Karikoski M, Gerke H, Dawes H, Laurila J, Ohlmeier S, Elima K, Hubscher SG, Weston CJ, Jalkanen S, Adams DH, Salmi M, Shetty S (2016) Stabilin-1 expression defines a subset of macrophages that mediate tissue homeostasis and prevent fibrosis in chronic liver injury. Proc Natl Acad Sci USA 113(33):9298–9303. https://doi.org/10.1073/pnas.1604780113 CrossRefPubMedPubMedCentral

32.

Irjala H, Alanen K, Grenman R, Heikkila P, Joensuu H, Jalkanen S (2003) Mannose receptor (MR) and common lymphatic endothelial and vascular endothelial receptor (CLEVER)-1 direct the binding of cancer cells to the lymph vessel endothelium. Cancer Res 63(15):4671–4676PubMed

33.

Palani S, Elima K, Ekholm E, Jalkanen S, Salmi M (2016) Monocyte stabilin-1 suppresses the activation of Th1 lymphocytes. J Immunol 196(1):115–123. https://doi.org/10.4049/jimmunol.1500257 CrossRefPubMed

Title: Microlocalization and clinical significance of stabilin-1+ macrophages in treatment-naïve patients with urothelial carcinoma of the bladder
Authors: Bo Wang
Hao Huang
Meihua Yang
Wenjuan Yang
Zhuowei Liu
Weibin Hou
Hong Zeng
Zhihua He
Tianxin Lin
Jian Huang
Publication date: 01-03-2020
Publisher: Springer Berlin Heidelberg
Keywords: Bladder Carcinoma
Bladder Carcinoma
Urothelial Cancer
Urothelial Cancer
Published in: World Journal of Urology / Issue 3/2020
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-019-02853-0

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Microlocalization and clinical significance of stabilin-1⁺ macrophages in treatment-naïve patients with urothelial carcinoma of the bladder

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2020

Evidence-based approach to active surveillance of prostate cancer

Level of knowledge on radiation exposure and compliance to wearing protective equipment: where do endourologists stand? An ESUT/EULIS survey

Multivariate risk prediction tools including MRI for individualized biopsy decision in prostate cancer diagnosis: current status and future directions

A critical appraisal of biomarkers in prostate cancer

Role of androgen receptor splice variants, their clinical relevance and treatment options

New predictive nomograms for non-muscle-invasive bladder cancer: it is all about the details